Relative Bioavailability of Pimasertib in Cancer Patients
Status: | Completed |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 80 |
Updated: | 5/5/2014 |
Start Date: | November 2013 |
End Date: | October 2014 |
Contact: | US Medical Information |
Phone: | 888-275-7376 |
A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients
This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over
trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in
cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial
extension phase).
trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in
cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial
extension phase).
Inclusion Criteria:
- Pathologically confirmed solid tumors, either refractory to standard therapy or for
which no effective standard therapy is available, with a measurable disease as
defined by RECIST v1.1
- An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or
equal to 1
- Other protocol defined inclusion criteria could apply
Exclusion Criteria:
- Disease conditions or concomitant medication that may significantly influence the
conduct of the trial or an abnormal electrocardiogram (ECG) or blood pressure at
Screening as defined in the protocol
- Treatment with strong inhibitors or inducers of cytochrome P450 2C19 (CYP2C19) and
CYP3A4 including fruit juices or beverages containing these substances
- History of prior mitogen-activated protein kinase/extracellular signal-regulated
kinase (MAPK/ERK) kinase (MEK) inhibitor exposure (including, pimasertib) or
progression of disease on MEK inhibitors
- Evidence of a retinal vein occlusion (RVO) on fluorescein angiogram or a history of
RVO
- Life expectancy of less than 12 weeks
- Other protocol defined exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
